Idéal Investisseur
Français English
CAC 40 : Market open – update pending
8 368,91 pts
+0.09%


Last updated : 13/11/2026 - 17h35 (last close)
Update in progress
🏠 Home   ➤    Stock news

Aelis Farma: second favorable opinion to continue the AEF0217 trial in Down syndrome

The independent Data Monitoring Committee (IDMC) has recommended that the Phase 2b trial of AEF0217 in Down syndrome continue without modification. This recommendation is based on a blinded interim analysis of safety data from 74 participants.

According to the press release published on November 16, 2026, the committee also issued a favorable opinion on the possible initiation of a 12-month open-label extension study.


Aelis Farma: second favorable opinion to continue the AEF0217 trial in Down syndrome

No serious adverse events, two mild effects potentially related to the product

This second review expands on the first one, announced in July 2026. The latter covered 42 participants, 32 of whom had completed four weeks of treatment. The new analysis includes 54 participants who received at least 12 weeks of treatment.

At the data cutoff on September 14, 2026, 23 participants (31.1%) had reported a total of 42 treatment-emergent adverse events. All were of mild intensity, with the exception of one transient vasovagal episode of moderate intensity, judged by the investigator to be unrelated to the product.

Only two events, vomiting and acne, were assessed as potentially related to the treatment. No serious or severe adverse events were reported, nor any treatment discontinuation due to an adverse event.

Laboratory tests, electrocardiograms, and vital signs revealed no signal related to the treatment. Among the 14 adolescents aged 16 and 17, the proportion of affected participants (28.6%) is comparable to that of adults (31.7%).

As the analysis was conducted in a blinded manner, these data do not distinguish participants receiving placebo from those receiving one of the three doses of AEF0217 (0.1, 0.2, or 0.6 mg).

An extension study under consideration, results expected by the end of 2027

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

The IDMC's opinion also covers a one-year open-label extension study, which could follow the Phase 2b trial while maintaining independent safety monitoring. According to the company, it would accelerate the collection of the long-term tolerability data required for marketing authorization applications.

As of November 4, 2026, 108 participants had been randomized out of the 188 planned in France, Spain, and Italy. Of these, 38 had completed the 24 weeks of treatment.

Clinical data, intended to confirm the efficacy observed in Phase 1/2, are expected by the end of 2027, in line with the previously announced timeline.

Pier Vincenzo Piazza, Chief Executive Officer, linked this assessment to the retrospective study recently published by the group. According to him, this study suggests that the benefits previously observed “translate into significant improvements in daily life”.

The coordinating investigator, Prof. Rafael de la Torre Fornell, for his part awaits the completion of the trial “in order to determine whether the encouraging results previously observed with AEF0217 can be confirmed in this broader population”.



Sector Pharmacie et biotechnologies › Biotechnologies


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0 millions d'euros
  • Quarterly revenue: 0 millions d'euros
  • Net income: -2,4 millions d'euros
  • -2,2 millions d'euros
Guidance from the release
  • « Nous abordons le second semestre 2026 avec confiance » (mot du DG) ; « la trésorerie disponible […] lui permet de financer ses activités jusqu'au début de l'année 2028, sur la base des hypothèses suivantes : […] en obtenant des reports d'échéances de remboursement, en cours de négociation, pour 0,5 million d'euros »
Risks mentioned
  • Execution of the AEF0217 Phase 2b clinical study in three countries is subject to recruitment progressing on schedule and regulatory compliance
  • Financial visibility through early 2028 is dependent on cost control plan execution and successful securing of non-dilutive funding
  • Business development efforts for AEF0117 require identification of an appropriate industry partner to finance next development stages
Opportunities identified
  • Positive EMA Pediatric Committee opinion on AEF0217 Pediatric Investigation Plan secures development pathway in pediatric populations through young adults
  • €458,000 France 2030 grant award in April 2026 accelerates development of new CB1-SSi compounds for obesity and metabolic diseases without dilution
  • AEF0217 Phase 2b international study (France, Spain, Italy) advancing on schedule with 188 participants and expected results before end of Q4 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours